Global Regenerative Medicine For Cartilage Market

The cell culture consumables and equipment global market consist of sales of cell culture consumables, equipment, and related service. The services include only installation and maintenance services offered by equipment manufacturers. Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuges and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The global cell culture consumables and equipment market size is expected to grow from $9.86 billion in 2021 to $10.99 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The global cell culture equipment market is expected to grow to $16.05 billion in 2026 at a CAGR of 9.9%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. Visikol launched OpenLiver 3D cell culture models in January 2019 to enter into 3D cell culture technology. FDA regulates the cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment FDA states that if the equipment is not labeled or mentioned as sterile, it would be removed from good manufacturing practices of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. Thermo Fisher acquired Brammer Bio for $1.7 billion in March 2019. Brammer Bio is a contract development and manufacturing organization (CDMO) for cell and gene treatment-centered biotechs. This transaction will strengthen Thermo Fisher to grow faster and expand the cell culture market in other countries. Brammer Bio is formed through the merger of Florida Biologix and Brammer Biopharmaceuticals and is headquartered in Cambridge, MA. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. The regions covered in the global cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cell culture consumables and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cell culture consumables and equipment market is segmented - 1) By Product: Consumables, Instruments 2) By End-User: Industrial, Biotechnology, Agriculture, Others 3) By Application: Vaccination, Toxicity Testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem Cell Technology, Regenerative Medicine, Others 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges

The arthroscopy devices and equipment market consist of sales of arthroscopy devices and equipment and related services. Arthroscopy devices are used in arthroscopy procedures (a minimally invasive procedure) for the diagnosis and treatment of joint problems such as torn cartilage, ACL, and sports-related injuries conducted on hip, knee, shoulder, spine, ankle, wrist, and elbow. The main products in the arthroscopy devices and equipment are arthroscopes, arthroscopy shavers, arthroscopy fluid management system, arthroscopy radiofrequency system, arthroscopy visualization system, and arthroscopy implants. Arthroscopes are to see inside the joint using a camera lens and a light. The arthroscopy devices and equipment provide applications in knee arthroscopy, hip arthroscopy, spine arthroscopy, foot and ankle arthroscopy, shoulder and elbow arthroscopy, and others. These are used by hospitals, ambulatory care, and trauma centers. The global arthroscopy devices and equipment market size is expected to grow from $3.78 billion in 2021 to $4.21 billion in 2022 at a compound annual growth rate (CAGR) of 11.4%. The global arthroscopy device market size is expected to grow to $6.09 billion in 2026 at a CAGR of 9.7%. A rise in product recalls is one of the restraints for the arthroscopy treatment devices and equipment market. Product recall is a process of retrieving all defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears all the cost of fixing the defective product and the cost of replacement. This replacement cost for a large number of products can go up to multi-million dollars, restraining the growth of the company and for the whole market as well. For example, in April 2019, Brainlab AG recalled spine and trauma 3-dimensional navigation due to inaccurate exposure that could lead to erroneous use. The arthroscopy device and equipment industry is witnessing a rise in mergers and acquisition activity. Major companies in the arthroscopy device market strategically acquired start-ups and mid-sized companies to broaden their products and services. For instance, in 2019, Smith & Nephew acquired Ceterix orthopedics to expand its product portfolio on NovoStitch Pro Meniscal Repair System, a knee repair device, and capitalize on the rising demand. Anika Therapeutics is in strategic partnerships with industry leaders such as DePuy Synthes, Mitek Sports Medicine, Medtronic, and Boehringer Ingelheim to develop new orthrobiologics. Medicines and Healthcare products Regulatory Agency (MRHA), a regulatory body for arthroscopic and orthopedic devices of the UK, sent an urgent field safety notice to Stryker Corporation, a medical and Orthopedics device manufacturer, initiating a lot-specific recall for the Stryker hip Products. The notice was sent as the implantation devices were either larger or smaller than the intended device. This impacted patient’s health by insufficient soft tissue tension, excessive stress in soft tissue, hip instability, and risks associated with revision surgeries. To reduce incidences associated with these devices MRHA has sent an urgent field safety notice to take corrective action by returning to a supplier to conduct an investigation and correct the device. In January 2021, Smith+Nephew, a company operating in the arthroscopy devices and equipment based in the UK acquired Extremity Orthopaedics for a deal amount of $240 million. With this acquisition, Smith+Nephew expands and strengthens its portfolio in extremities. Extremity Orthopaedics is a company operating in medical technology and arthroscopy devices and equipment market-based in the United States. Major players in the arthroscopy devices and equipment market are Arthrex Inc., Smith & Nephew, ConMed Corporation, Stryker, Medtronic, Karl Storz SE & CO. KG, ArthroCare, Richard Wolf Gmbh, Karl Storz SE & CO. KG, and DePuy Synthes Companies. North America was the largest region in arthroscopy devices and equipment market in 2021. Western Europe was the second-largest region in the global arthroscopy equipment market. The regions covered in the global arthroscopy devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the arthroscopy devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The global arthroscopy devices and equipment market is segmented - 1) By Product: Arthroscopes, Arthroscopy Shavers, Arthroscopy Fluid Management System, Arthroscopy Radiofrequency System, Arthroscopy Visualization System, Arthroscopy Implants 2) By Application: Knee Arthroscopy, Hip Arthroscopy, Spine Arthroscopy, Foot and Ankle Arthroscopy, Shoulder and Elbow Arthroscopy, Others 3) By End-User: Hospitals, Ambulatory Care, Trauma Centers

The joint reconstruction devices and equipment market consist of sales of joint reconstruction devices and equipment and related services. Joint reconstruction devices and equipment are used in joint reconstruction procedures. The main product types of joint reconstruction devices and equipment are knee reconstruction devices, hip reconstruction devices, and extremity reconstruction devices. Hip reconstruction devices are medical devices intended to restore mobility and relieve pain associated with arthritis and other hip diseases or injuries. The various applications involved are arthrodesis, arthroscopy, joint replacement surgery, osteotomy, resurfacing surgery, and small joint surgery. The various end-users are hospitals, orthopedic clinics, and ambulatory surgical centers. The global joint reconstruction devices and equipment market size is expected to grow from $11.84 billion in 2021 to $12.98 billion in 2022 at a compound annual growth rate (CAGR) of 9.6%. The global joint reconstruction devices market size is expected to grow to $17.6 billion in 2026 at a CAGR of 7.9%. The presence of a large pool of patients in joint reconstruction diseases is driving the market. Patients are preferring joint replacement treatment instead of other treatments for joint diseases, because of increased safety and reliability. The rise in joint reconstruction diseases such as osteoarthritis, knee and hip injury, road accident, cartilage, and labral injury is increasing the patient pool. For instance, osteoarthritis is a common disorder of joints that mainly affects the geriatric population across the globe. This condition can be treated by joint replacement surgeries using orthopedic knee and hip implants surgery According to the Arthritis Foundation, about 67 million people are expected to suffer from arthritis by 2030. This rise in the patient pool for joint diseases is driving the demand for the joint reconstruction devices and equipment market, significantly impacting the market growth. The joint reconstruction devices and equipment market is being restrained due to the high rate of product recalls. The medical devices industry including joint reconstruction devices is seeing a significant spike in product recalls during recent years, due to defects, concerns regarding patient safety, software issues, mislabeling issues, quality issues, and others, thereby affecting the growth of the market. For example, DePuy had to recall several of its Attune knee replacement systems, due to safety concerns. Similarly. Similarly, Zimmer Biomet, a USA-based medical device company, recalled its 5 products related to the Oxford product line due to racking and separation issues. The product line recalled included the Oxford Partial Knee System Right and Left Medial Tibial Tray (of various sizes), and the Oxford Unicompartmental Knee Phase 3 Tibial Impactor. This high recall rate is affecting the sales of joint reconstruction devices and hampering the growth of the market. Companies in joint reconstruction devices are increasingly investing in 3D printing technology due to its significant improvement over traditional joint reconstruction surgery. This technique uses for reconstructions of bones as a base before the surgery plan so the patient can get a preoperative MRI or CT scan. These features are particularly beneficial for patients in terms of safety concerns, which can affect adherence to treatment regimens. For instance, in 2019, Conformis, a USA-based developer and manufacturer of knee implants, launched a hip implant using 3D printing technology as per patients’ specifications. Joint reconstruction devices and equipment are Class III devices that come under the orthopedic devices market and orthopedic devices manufacturing is monitored by regulatory bodies such as the US Food and Drug Administration (FDA). For instance, under the Federal Food, Drug, and Cosmetic Act (FFDCA), all medical device manufacturers must register their facilities and list their devices with US FDA, and follow general controls requirements. The manufacturers can gain premarket approval through 2 methods. The first method consists of conducting clinical studies and submitting a premarket approval (PMA) application which includes evidence providing reasonable assurance that the device is safe and effective. The other method involves submitting a 510(k)-notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. In March 2019, Exactech, a USA-based developer, manufacturer, and distributor of orthopedic implant devices, related surgical instrumentation, and biologic services acquired XpandOrtho for an undisclosed amount. This acquisition is expected to enhance ExactechGPS® computer-assisted surgery system using XpandOrtho’s technology. XpandOrtho is a USA-based designer of soft tissue balancing instruments for knee replacement surgery. Major players in the joint reconstruction devices and equipment market are Smith & Nephew, Stryker, Zimmer Biomet, B. Braun Melsungen, Wright Medical Group, DePuy Synthes, Johnson & Johnson, Aesculap Implant Systems Inc, and Arthrex Inc. North America was the largest region in the joint reconstruction devices and equipment market in 2021. Asia Pacific was the second largest market in the global joint reconstruction equipment market. The regions covered in the global joint reconstruction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the joint reconstruction devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global joint reconstruction devices and equipment market is segmented - 1) By Product Type: Knee Reconstruction Devices, Hip Reconstruction Devices, Extremity Reconstruction Devices 2) By Application: Arthrodesis, Arthroscopy, Joint Replacement Surgery, Osteotomy, Resurfacing Surgery, Small Joint Surgery 3) By End-User: Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers

Induced Pluripotent Stem Cell (iPSC) Market Definition

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as hepatocytes, fibroblasts, keratinocytes, and neurons. Induced pluripotent stem cell (iPSC) are derived from somatic cells such as skin or blood cells that have been reprogrammed, by ectopic introduction of transcriptional factor genes, back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes.

The stem cell market consists of sales of stem cells products such as human embryonic stem cell, induced pluripotent stem cell and adult stem cell. Stem cells are the autologous or allogenic cells that can grow into many types of cells in in-vivo and in-vitro environment. Stem cells therapy is designed to aid physician in performing medical treatment of neurodegenerative diseases, diabetes and heart disease. The main product types of stem cell are adult stem cell, human embryonic stem cell, induced pluripotent stem cell and others. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different sources include autologous, allogeneic and used in various applications such as regenerative medicine, drug discovery and development. The global stem cell market size is expected to grow from $11.59 billion in 2021 to $12.72 billion in 2022 at a compound annual growth rate (CAGR) of 9.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The stem cell market is expected to reach $18.51 billion in 2026 at a CAGR of 9.8%. There is an increase in the prevalence of chronic diseases worldwide which drives the stem cell market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. According to WHO, in 2020, prevalence of chronic disease increased to 57%. As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward. Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year. The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market. The acceptance rate is particularly low in the Embryonic stem cell therapeutics. Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental. Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues. For example, if a person undergoes an unproven or experimental treatment it might make that person ineligible for future clinical trials or treatment options. For instance, in USA, an unproven stem cell offering three elderly women were blinded after getting stem cells derived from fat tissue at a clinic in Florida. These factors are limiting the number of people opting for stem cell therapies, thus restraining the growth of the market. Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (iPSC) to boost the efficiency of stem cell therapies. IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes. These IPSCs are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily. A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells. Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis for disease modeling and drug discovery. The Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) is the regulator in the US, for Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases. The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products. In August 2021, Catalent, a US-based provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and cell and gene treatments acquired RheinCell Therapeutics GmbH for an undisclosed amount. With this acquisition Catalent aims to deploy RheinCell's expertise and deep knowledge in iPSC cell lines that will boost Catalent’s cell therapy portfolio, allowing them to offer iPSC banks to their customers as a premium source for their therapeutic development pathway. RheinCell Therapeutics GmbH is a Germany based company that specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPS cells). Major players in the stem cell market are Anterogen Co., Ltd, Mesoblast Ltd, Osiris TherapeuticsInc, AlloSource, Cellular Engineering Technologies, BIOTIMEInc, Astellas Pharma USInc, Vericel, RTI SurgicalInc and Takara Bio Company. The regions covered in the stem cell market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global stem cells market is segmented - 1) By Source: Autologous, Allogeneic 2) By Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, Others 3) By Application: Regenerative Medicine, Drug Discovery and Development

The 3D cell culture technologies market consists of sales of 3D cell culture technologies and related services. Some of the 3D cell culture technologies include microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. The 3D cell culture technologies market does not include sales of cell culture consumables and instruments. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The global 3D cell culture technologies market size is expected to grow from $2.03 billion in 2021 to $2.39 billion in 2022 at a compound annual growth rate (CAGR) of 18.0%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The 3D cell culture technologies market is expected to reach $4.71 billion in 2026 at a CAGR of 18.5%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. According to the U.S. government information on organ donation and transplantation, 39,718 transplants were performed in 2019 and above 109,000 people are waiting for the transplant as of September 2020. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement into the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include the consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based startup that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC, Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc, VWR International, LLC, WHEATON IndustriesInc, and Sartorius AG. The regions covered in the 3D cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global 3D cell culture technologies market is segmented - 1) By Type: Scaffold-Based, Scaffold-Free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-Based: Hydrogels, Polymeric Scaffolds, Micropatterned Surface Microplates 4) By Scaffold-Free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations and 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes and neurons. The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various application includes academic research, drug development and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, research laboratories. The global induced pluripotent stem cell (iPSC) market size is expected to grow from $ 2431.2 million in 2021 to $ 2640.80 million in 2022 at a compound annual growth rate (CAGR) of 8.6%. The growth in the iPSC market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The induced pluripotent stem cell market is expected to reach $ 3571.48 million in 2026 at a CAGR of 7.8%. Increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with induced pluripotent stem cells. Induced pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment. The potential risk of tumour is one of the major restraints on the growth of Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the induced pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in November 2019, Notch Therapeutics and Allogene Therapeutics announced a partnership and licencing contract to research and develop induced pluripotent stem cell (iPSC) AlloCAR treatment goods for early use of leukaemia, multiple myeloma and non-Hodgkin lymphoma. Another Example is in January 2019, the New York Stem Cell Foundation (NYSCF) Research Institute made a strategic partnership with Ngene Therapeutics Inc. (Ngene) for the treatment of new diseases that will hold the human stem cell research and techniques like novel gene editing which means replacement of DNA at a specific cell. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for induced pluripotent stem cell (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional Review Board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2019, Bayer, a Germany based pharmaceutical and life sciences company acquired BlueRock Therapeutics LP for $600 million. Through the deal, Bayer would own full rights to BlueRock’s CELL+GENE™ platform, which is designed to create stable master cell banks capable of virtually unlimited expansion and differentiation into any cell type in the body, using proprietary bioprocessing and manufacturing techniques. BlueRock Therapeutics LP is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc., Fate Therapeutics, ViaCyte, StemCells, Japan Tissue Engineering Co. Ltd, Fate Therapeutics and Japan Tissue Engineering Co. The regions covered in the induced pluripotent stem cell (iPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global induced pluripotent stem cell market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others 2) By Application: Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories

The cell culture market consists of sales of cell culture equipment and consumables for drug development and related services. Cell culture is the process by which cells are grown in suitable sterile environments under controlled conditions. Cell culture is one of the major tools used in molecular & cellular biology, manufacturing of medicines, and large-scale manufacture of biological compounds. The main types of cell culture are primary cell culture, secondary cell culture and cell line. Primary cell cultures are those that develop from tissue explants or specific cells extracted from the source tissue. The different medias include natural, artificial and is used in stem cell technologies, cancer research, biopharmaceutical, tissue engineering & regenerative medicine, others. The global cell culture market size is expected to grow from $20.28 billion in 2021 to $22.49 billion in 2022 at a compound annual growth rate (CAGR) of 10.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell culture market is expected to reach $34.01 billion in 2026 at a CAGR of10.9%. The rise in the demand for cell therapy is expected to drive the cell culture market. In cell therapy, viable cells are injected or implanted into a patient's body to cure a medicinal disease. Cell culture is a vital step in any cell-based therapy. According to the Cancer Research Institute (CRI), there are about 1,483 active cell therapies in development in 2020 compared to 1,011 in 2019. Cell culture is used in the development, manufacture, and commercialization of cell therapies and holds the potential to revolutionize the healthcare industry for the treatment of various diseases. Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market. The lack of skilled professionals is expected to hinder the cell culture market’s growth. The consequence of having unskilled workers can also be detrimental to the bottom line of a company, as even a small batch error can cost an organization millions of dollars. The regulatory agency that issues the facility's license requires an annual report that includes all failed batches, and if the failure rate is more than 5%, the plant may be at risk of losing the ability to sell its drug. Furthermore, according to a skills survey by the Cell and Gene Therapy Catapult (CGTC) in 2019, UK cell and gene therapy firms are worried about the shortage of skilled manufacturing staff for the expansion of their business. The lack of talent is expected to adversely impact the growth of the cell and gene therapy industry, thereby restraining the growth of the cell culture market. The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity. A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions, similar to how they would in a living organism. For instance, in July 2020, Rigenerand, an Italian company engaged in the production of innovative cell-based technology products for regenerative medicine and oncology, has launched a 3D bioreactor called VITVO handheld bioreactor to offer increased usability, sizing, closed system, and flexibility for 3D cell culture technologies. Similarly, Jellagen, a UK-based marine biotechnology company, launched JellaGel, a jellyfish collagen hydrogel, suitable for 3D cell culture and tissue engineering. In March 2020, Danaher, a US-based Fortune 500 science and technology company, has acquired the biopharma business of General Electric Life Sciences for an amount of $21.4 billion. As a part of Danaher, the company is to be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. GE Biopharma’s offerings included cell culture media, single-use technologies, process chromatography hardware & consumables, development instrumentation and consumables, and service. Major players in the cell culture market are Thermo Fisher Scientific Inc., Corning, Inc., Becton, Dickinson and Company, Eppendorf AG, Merck KGAA, Lonza Group AG, Sartorius AG, Promocell GmbH, Danaher and Sartorius. North America was the largest region in the cell culture market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cell culture market is segmented - 1) By Type: Primary Cell Culture, Secondary Cell Culture, Cell Line 2) By Media: Natural, Artificial 3) By Applications: Stem Cell Technologies, Cancer Research, Biopharmaceutical, Tissue Engineering & Regenerative Medicine, Others